Addition of abiraterone, docetaxel, bisphosphonate, celecoxib or combinations to androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC): a network meta-analysis

被引：0
|
作者：
Pui San Tan
Pedro Aguiar
Benjamin Haaland
Gilberto Lopes
机构：
[1] University of Oxford,Nuffield Department of Primary Care Health Sciences
[2] Clinical Oncology Sector,Population Health Sciences and Huntsman Cancer Institute
[3] Faculdade de Medicina do ABC,Sylvester Comprehensive Cancer Center
[4] University of Utah,undefined
[5] University of Miami,undefined
来源：
Prostate Cancer and Prostatic Diseases | 2018年 / 21卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：516 / 523
页数：7
相关论文
共 50 条
  • [31] Phase 3 Study of Androgen Deprivation Therapy (ADT) with Enzalutamide (ENZA) or Placebo (PBO) in Metastatic Hormone-Sensitive Prostate Cancer (MHSPC): The Arches Trial
    Horvath, Lisa
    Armstrong, Andrew J.
    Szmulewitz, Russell
    Petrylak, Daniel
    Villers, Arnauld
    Azad, Arun
    Alcaraz, Antonio
    Alekseev, Boris
    Iguchi, Taro
    Shore, Neal D.
    Rosbrook, Brad
    Sugg, Jennifer
    Baron, Benoit
    Chen, Lucy
    Stenzl, Arnulf
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 32 - 33
  • [32] Prostate-specific antigen (PSA) outcomes with darolutamide (DARO): Androgen-deprivation therapy (ADT) and docetaxel (DOC) in patients (pts) with high- and low-volume metastatic hormone-sensitive prostate cancer (mHSPC) in ARASENS
    Saad, F.
    Hussain, M.
    Tombal, B.
    Fizazi, K.
    Sternberg, C. N.
    Crawford, E. D.
    Boegemann, M.
    Tutrone, R.
    Littleton, N.
    Srinivasan, S.
    Verholen, F.
    Kuss, I.
    Smith, M. R.
    ANNALS OF ONCOLOGY, 2023, 34 : S964 - S964
  • [33] The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation
    McNamara, Megan
    Sweeney, Christopher
    Antonarakis, Emmanuel S.
    Armstrong, Andrew J.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2018, 21 (03) : 306 - 318
  • [34] The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation
    Megan McNamara
    Christopher Sweeney
    Emmanuel S. Antonarakis
    Andrew J. Armstrong
    Prostate Cancer and Prostatic Diseases, 2018, 21 : 306 - 318
  • [35] Additional cycles of docetaxel in combination with androgen deprivation therapy (D-ADT) in metastatic hormone- sensitive prostate cancer (mHSPC): Efficacy and feasibility analysis.
    Aydogdu, Can
    Urban, Florian
    Tamalunas, Alexander
    Berg, Elena
    Tz, Melanie Go Spacing Diaeresis
    Rodler, Severin
    Heinemann, Volker
    Stief, Christian
    Casuscelli, Jozefina
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [36] Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer
    Aguiar Jr, Pedro Nazareth
    San Tan, Pui
    Simko, Sarah
    Noia Barreto, Carmelia Maria
    Gutierres, Barbara de Souza
    del Giglio, Auro
    Lopes Jr, Gilberto de Lima
    EINSTEIN-SAO PAULO, 2019, 17 (02): : eGS4414
  • [37] Additional cycles of docetaxel in combination with androgen deprivation therapy (D-ADT) in metastatic hormone- sensitive prostate cancer (mHSPC): Efficacy and feasibility analysis.
    Aydogdu, Can
    Urban, Florian
    Tamalunas, Alexander
    Berg, Elena
    Goetz, Melanie
    Rodler, Severin
    Unterrainer, Lena
    Heinemann, Volker
    Stief, Christian G.
    Casuscelli, Jozefina
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [38] Efficacy and Safety of Androgen-Deprivation Therapy Combined with Docetaxel Plus Prednisone in High-Burden Metastatic Hormone-Sensitive Prostate Cancer
    Hu, Linjun
    Zhao, Qinxin
    Bai, Hongsong
    Xie, Chengming
    Shan, Xingli
    Lu, Dehu
    Chen, Yonghai
    Han, Dongdong
    Xiao, Zejun
    Tian, Jun
    Wang, Dong
    Bi, Xingang
    Xing, Nianzeng
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 4369 - 4377
  • [39] The Addition of Darolutamide to Androgen Deprivation Therapy and Docetaxel in a 55-Year-Old Man With Metastatic Hormone-Sensitive Prostate Cancer
    Crawford, David
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (07)
  • [40] Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy thorn Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer
    Francini, Edoardo
    Yip, Steven
    Ahmed, Shubidito
    Li, Haocheng
    Ardolino, Luke
    Evan, Carolyn P.
    Kaymakcalan, Marina
    Shaw, Grace K.
    Kantoff, Philip W.
    Taplin, Mary-Ellen
    Alimohamed, Nimira S.
    Joshua, Anthony M.
    Heng, Daniel Y. C.
    Sweeney, Christopher J.
    CLINICAL GENITOURINARY CANCER, 2018, 16 (02) : 130 - 134
12345